Europe’s CHMP Clears Sofosbuvir, Dolutegravir And Dalamanid
This article was originally published in The Pink Sheet Daily
As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.
You may also be interested in...
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will consider a new submission for AstraZeneca/Bristol-Myers Squibb’s dapagliflozin on Dec. 12. Filing includes several new studies and more long-term data.
The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.
Europe's CHMP takes divergent stance to FDA on dapagliflozin, clearing it for treating diabetes if AstraZeneca and Bristol-Myers Squibb conduct a post-marketing study. The committee also cleared ruxolitinib and ferumoxytol, but rejected Folotyn, for EU marketing.